In addition, pharmacological inhibition of PPARγ with antagonist T0070907 significantly increased the expression of key cancer immunity-enhancing inflammatory factors including CCL2 and IL8 in the PPARG-amplified 5637 cells (Fig. 5g). Here, CCL2 is linked to cancer.